Neogen (NEOG) Competitors

Haemonetics (NYSE:HAE) and Neogen (NASDAQ:NEOG) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, media sentiment, community ranking, profitability, risk and earnings.

Does the media prefer HAE or NEOG?

In the previous week, Neogen had 15 more articles in the media than Haemonetics. MarketBeat recorded 22 mentions for Neogen and 7 mentions for Haemonetics. Neogen's average media sentiment score of 0.21 beat Haemonetics' score of -0.26 indicating that Neogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Haemonetics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Neogen	5 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral

Is HAE or NEOG more profitable?

Haemonetics has a net margin of 9.47% compared to Neogen's net margin of -52.12%. Haemonetics' return on equity of 23.66% beat Neogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Haemonetics	9.47%	23.66%	8.82%
Neogen	-52.12%	2.89%	1.98%

Do analysts recommend HAE or NEOG?

Haemonetics currently has a consensus price target of $97.89, suggesting a potential upside of 35.66%. Neogen has a consensus price target of $9.00, suggesting a potential upside of 53.19%. Given Neogen's higher probable upside, analysts clearly believe Neogen is more favorable than Haemonetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Haemonetics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Neogen	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Do institutionals and insiders hold more shares of HAE or NEOG?

99.7% of Haemonetics shares are owned by institutional investors. Comparatively, 96.7% of Neogen shares are owned by institutional investors. 1.8% of Haemonetics shares are owned by insiders. Comparatively, 1.1% of Neogen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Which has stronger earnings & valuation, HAE or NEOG?

Haemonetics has higher revenue and earnings than Neogen. Neogen is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Haemonetics	$1.36B	2.55	$117.56M	$3.31	21.80
Neogen	$906.00M	1.41	-$9.42M	-$2.23	-2.63

Which has more risk & volatility, HAE or NEOG?

Haemonetics has a beta of 0.36, suggesting that its stock price is 64% less volatile than the S&P 500. Comparatively, Neogen has a beta of 1.84, suggesting that its stock price is 84% more volatile than the S&P 500.

Does the MarketBeat Community favor HAE or NEOG?

Haemonetics received 73 more outperform votes than Neogen when rated by MarketBeat users. Likewise, 61.74% of users gave Haemonetics an outperform vote while only 56.46% of users gave Neogen an outperform vote.

Company	Underperform	Outperform
Haemonetics	Outperform Votes 405 61.74%	Underperform Votes 251 38.26%
Neogen	Outperform Votes 332 56.46%	Underperform Votes 256 43.54%

Summary

Haemonetics beats Neogen on 15 of the 19 factors compared between the two stocks.